Posts Tagged ‘FH’
Your Doctor Prescribed a Medicine, But Will You Get It?
Seth J. Baum, MD In 2013 Dr. Tom Frieden, Director of the CDC, judiciously proclaimed that “even one preventable death is one too many.” Just three years later we are mired in debates concerning cost effectiveness of innovative medicines. We argue about not only the price of drugs, but also the monetized value of a…
Read MoreAccessing PCSK9 Inhibitors: An Ongoing Bottleneck for Patients and Their Doctors
by Seth J. Baum MD PCSK9 inhibitors are the most significant advance in the management of elevated cholesterol in the last 3 decades. These injectable medications are indisputably revolutionary: They provide intensive and predictable reduction of LDL cholesterol in even our most difficult-to-treat patients. So, you would think that insurance providers would embrace them. Not…
Read MoreResponse to Matt Perrone‘s April 20th Associated Press Piece on PCSK9 Inhibitors
by Seth J. Baum MD I was fortunate to have the opportunity to speak at length with Matt Perrone prior to his submitting an April 20th article on the PSCK9 inhibitors’ unexpectedly low uptake in the medical community. His piece was excellent; yet it failed to address the most salient aspect of this problem: Patients…
Read MoreFH Foundation’s National FH Registry Illustrates U.S. FH Population’s Risk for Early CHD
Important research recently published in the American Heart Association’s journals illustrates that the cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the US remain poorly described. The study consisted of a cross-sectional analysis of 1295 adults with heterozygous FH enrolled in the FH Foundation’s CASCADE-FH Registry from 11 US lipid…
Read MorePCSK9 Inhibitors: Why Are They Under-Prescribed?
by Seth J. Baum, MD A recent article by Caroline Humer and Ransdell Pierson for Reuters reported on the unexpectedly paltry number of prescriptions for PCSK9 inhibitors, the revolutionary cholesterol lowering drugs that were FDA approved in the summer of 2015. Insurance providers had viewed these costly medications as a potentially grave threat to their…
Read More#Know FH – The 2015 FH Summit
by Seth J. Baum, MD Flying back from the FH Foundation’s third annual FH Summit I was suffused by assorted feelings and thoughts. I attend many meetings; yet, this one is unique. A conglomerate of stakeholders congregate to discuss past, present, and future issues about a disease that has only recently captured the hearts, minds,…
Read MoreCaution: Economists, Not Doctors Might be Prescribing Your Medicine
by Seth J. Baum, MD It’s National Cholesterol Education Month and we have fittingly entered a new era in lipid management. We now know that elevated LDL cholesterol causes heart attacks and strokes. Studies of all types have proved this. The most persuasive proof comes from genetics, specifically Mendelian Randomization studies. Recently our increased genetic…
Read MoreFDA Gives Premarket Approval for Modification of LDL Indications for Use of Lipoprotein Apheresis System
by Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA The FDA has granted premarket approval to Kaneka Pharma America’s application requesting approval for modification of the indications for use of their Liposorber LA-15 System. The major gain for patients is that LDL can now be 160 or greater whereas previously it had to be 200…
Read More